Management of peritoneal gastric metastasis: An update

Eur J Surg Oncol. 2025 Jun;51(6):109731. doi: 10.1016/j.ejso.2025.109731. Epub 2025 Feb 26.

Abstract

Importance: Peritoneal metastases from gastric cancer (PMGC) are associated with poorer median survival and systemic chemotherapy remains the standard of care. This narrative review summarizes the current evidence for medical and surgical treatment of PMGC.

Observations: Treatment is moving to local ways of administering chemotherapy, either intraperitoneal normothermic chemotherapy, laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) or even pressurized intraperitoneal aerosol chemotherapy. Furthermore, cytoreductive surgery±HIPEC could also be an alternative in specific situations.

Conclusions: and relevance: This review provides an updated summary of existing strategies that can be discussed in the management of patients with PMGC.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Cytoreduction Surgical Procedures / methods
  • Humans
  • Hyperthermic Intraperitoneal Chemotherapy* / methods
  • Laparoscopy
  • Peritoneal Neoplasms* / secondary
  • Peritoneal Neoplasms* / therapy
  • Stomach Neoplasms* / pathology
  • Stomach Neoplasms* / therapy

Substances

  • Antineoplastic Agents